Effects of Closed-loop Automatic Control of FiO2 in Extremely Preterm Infants (FiO2-C)

Effects of Closed-loop Automatic Control of the Inspiratory Fraction of Oxygen (FiO2-C) on Outcome of Extremely Preterm Infants - a Randomized Controlled Parallel Group Multicenter Trial for Safety and Efficacy

Extremely low gestational age neonates (ELGANs), i.e. those born at <28 weeks, frequently experience intermittent hypoxemic/hyperoxemic episodes. Observational data indicate that severe and prolonged hypoxemic episodes are associated with retinopathy of prematurity (ROP), impaired long-term development and death. Closed-loop automated control of the inspiratory fraction of oxygen (FiO2-C) reduces time outside the oxygen target range, decreases number and duration of hypo- and hyperoxemic episodes, and reduces caregivers' workload. The proposed observer-blinded randomized controlled trial was designed and will be powered to compare the effect of FiO2-C in addition to manual adjustments, in comparison with manual adjustments of FiO2 only, on death and severe complications of prematurity thought to be related to hypoxia/hyperoxia and neurodevelopmental impairment in ELGANs. The results of this trial may help to improve the quality of life of ELGANs and reduce the burden of significant morbidity as well as costs for health care and society

Study Overview

• Status: Active, not recruiting
• Conditions: Infant,Premature
• Intervention / Treatment: Device: closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)

Detailed Description

Approximately 0.5% of all neonates (i.e., about 25,000 infants per year in Europe) are extremely low gestational age neonates (ELGANs), i.e. have a gestational age (GA) of <28 completed weeks at birth. ELGANs have higher incidences of mortality, retinopathy of prematurity (ROP), chronic lung disease and other risks of prematurity as well as severe neurodevelopmental impairment.

The vast majority of ELGANs require supplemental oxygen in addition to mechanical respiratory support (including CPAP). Irrespective of the SpO2 target, the vast majority of ELGANs suffers from recurrent intermittent hypoxemic and (as a consequence of inappropriate adjustments of FiO2) hyperoxemic episodes. Recurrent intermittent hypoxic episodes - i.e. wide fluctuations in oxygen levels - are associated with an increased risk of ROP and there are data that suggest that late deaths and neurodevelopmental impairment are also linked to them.

Continuous positive airway pressure (CPAP) has been shown to reduce extubation failure in preterm infants, which may in part be due to a reduced frequency and severity of apnea of prematurity and stabilized functional residual capacity during apnea. Keeping oxygen levels (i.e., SpO2) stable despite irregular breathing patterns in ELGANs, requires frequent adjustments of the FiO2 which is both challenging, time consuming, and often impossible due to limited personnel resources.

FiO2-Controllers have been developed by several manufacturers of infant ventilators. They reduce the burden of hyper-/hypoxemia in infants while being safe and accurate in very short-term studies. The effects of FiO2-C on clinically relevant outcome measures and the safety of long-term continuous application, however, have yet to be elucidated. Hence there is now a window of opportunity to assess this new technology for benefits and harms, before it is implemented into neonatal care without appropriate evaluation of its safety and efficacy.

• Study Type: Interventional
• Enrollment (Actual): 1065
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Xi'an, China, 710061
    • Northwest Women's and Children's Hospital
• Germany
  • Amberg, Germany, 92224
    • Klinikum St. Marien - Klinik für Kinder und Jugendliche
  • Augsburg, Germany, 86154
    • Josefinum - Klinik für Kinder und Jugendliche
  • Bad Kreuznach, Germany, 55543
    • Diakonie Krankenhaus der Kreuznacher Diakonie
  • Bremen, Germany, 29277
    • Klinikum Links der Weser
  • Dresden, Germany, 01307
    • Universitätsklinikum Dresden
  • Düsseldorf, Germany, 40225
    • Universitatsklinikum Dusseldorf
  • Erfurt, Germany, 99089
    • Helios Klinikum Erfurt
  • Esslingen, Germany, 73730
    • Klinikum Esslingen GmbH - Klinik für Kinder und Jugendliche
  • Freiburg, Germany, 79106
    • Zentrum für Kinder- und Jugendmedizin
  • Hannover, Germany, 30625
    • Medizinische Hochschule Hannover
  • Heidelberg, Germany, 69120
    • Universitätsklinikum Heidelberg
  • Karlsruhe, Germany, 76133
    • Stadtisches Klinikum Karlsruhe
  • Leipzig, Germany, 04103
    • University Hospital Leipzig
  • München, Germany, 80804
    • Städtisches Klinikum - Klinik für Neonatologie
  • München, Germany, 81545
    • München Klinik Harlaching
  • München - Großhadern, Germany, 81377
    • Universitätsklinikum München
  • Münster, Germany, 48149
    • Klinik für Kinder- und Jugendmedizin
  • Nürnberg, Germany, 90419
    • Klinik Hallerwiese - Cnopf'sche Kinderklinik
  • Regensburg, Germany, 93049
    • Krankenhaus Barmherzige Brüder
  • Reutlingen, Germany, 72764
    • Klinikum am Steinenberg
  • Schweinfurt, Germany, 97422
    • Leopoldina Krankenhaus der Stadt Schweinfurt GmbH
  • Speyer, Germany, 67346
    • Diakonissen-Stiftungs-Krankenhaus Speyer
  • Stuttgart, Germany, 70174
    • Klinikum Stuttgart, Olgahospital
  • Tübingen, Germany, 72076
    • University Hospital Tübingen
  • Ulm, Germany, 89075
    • Universitatsklinikum Ulm
  • Villingen-Schwenningen, Germany, 78052
    • Schwarzwald-Baar-Klinik
  • Winnenden, Germany, 71364
    • Rems-Murr-Kliniken gGmbH
• Netherlands
  • Maastricht, Netherlands, 6229
    • Kindergeneeskunde Maastricht Universitair Medisch Centrum
  • Veldhoven, Netherlands, 5504 DB
    • Maxima Medical Center
  • Zwolle, Netherlands, 8025
    • Isala Kliniek Zwolle - Location Sophia
• United Kingdom
  • Middlesbrough, United Kingdom
    • The James Cook University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 3 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Preterm infants with a gestational age (GA) at birth of 23+0/7 - 27+6/7 weeks

Exclusion Criteria:

• Decision for palliative care
• congenital anomalies
• postnatal age > 48h
• missing parental consent
• lack of device enabling closed-loop automatic control of FiO2

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental intervention; closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)	Device: closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C); Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol
No Intervention: Control intervention; Standard care, i.e. manual adjustments of the FiO2 only

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary outcome I: composite outcome of death, severe retinopathy of prematurity (ROP), chronic lung disease of prematurity (BPD), necrotizing enterocolitis (NEC)	The primary outcome I is a composite of any of the following: Death; Severe retinopathy of prematurity (severe ROP, as defined in 7.3.1); Chronic lung disease of prematurity (BPD, according to the physiological definition, which is described in detail in the study protocol); Necrotizing enterocolitis (NEC, as defined in the study protocol) until discharge from hospital The primary endpoint I will be analysed between the two intervention groups using a stratified chi2-test and Cochrane Mantel-Haenszel statistics will be presented (risk ratios and 95%-confidence intervals). The factors considered for randomization (center, sex and gestational age at birth (<26 weeks and ≥26 weeks) will also be used for analysis.	until/at post-menstrual age (PMA) 36 weeks (death, BPD and NEC) and at latest at PMA 44 weeks for severity of ROP
Primary outcome II: composite of death or neurodevelopmental impairment (NDI)	The primary outcome II is a composite of any of the following: • death or neurodevelopmental impairment (defined as at least one of the following components: motor disability (GMFCS 2-5), language or cognitive delay (language composite score < 85 or cognitive composite score < 85 on Bayley Scales of Infant Development, 3rd edition) or severe visual or hearing impairment (need for a hearing aid or cochlear implant)). In case of missing Bayley III test results, Bayley II results, other developmental test results or PARCA-R parent questionnaire results may substitute for the Bayley III test results in a hierarchical manner described in the study protocol. The primary outcome II will be analysed between the two intervention groups using chi2-test and Cochrane Mantel-Haenszel statistics will be presented (risk ratios and 95%-confidence intervals). The factors considered for randomization (center, sex and gestational age at birth (<26 weeks and ≥26 weeks) will also be used for analysis.	at 24 months of age corrected for prematurity

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Death	Death rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.	24 months of age corrected for prematurity
ROP Severity Score	The most severe grade of ROP according to 25 categories currently developed by the working group of the international neonatal consortium (may have to be adapted as the consensus process proceeds), documented in either eye (for at least 2 consecutive examinations) will be analysed using Wilcoxon-Mann-Whitney test.	at latest at PMA 44 weeks
Severe ROP	defined as: ROP stage 0, 1 or 2 (in Zone 2 or 3) = no/non-severe ROP versus 3, 4 or 5, or AP-ROP, or any ROP in Zone 1, or any treatment for ROP = severe ROP. Rates of severe ROP will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.	at latest at PMA 44 weeks
bronchopulmonary Dysplasia (BPD)	As part of routine care, the presence of BPD will be determined at 36 weeks postmenstrual age (PMA) according to the physiological definition of Walsh et al. [Walsh, J Perinatol 2003]. BPD rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.	until 36 weeks PMA
Necrotizing enterocolitis (NEC)	NEC (modified Bell stage ≥ IIA according to [Bell, Ann Surg 1978]) or intestinal perforation will be diagnosed at surgery, at autopsy, or by either the finding of pneumatosis intestinalis, hepatobiliary gas, or free intraperitoneal air on abdominal x-ray, or by demonstration of gas (bubbles) in the portal vein on abdominal ultrasound or abdominal x-ray. NEC rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.	until 36 weeks PMA
Neurodevelopmental impairment (NDI)	NDI is defined as at least one of the following components: motor disability (modified GMFCS 2-5), language or cognitive delay (language composite score < 85 or cognitive composite score < 85 on Bayley Scales of Infant Development, 3rd edition) or severe visual or hearing impairment (need for a hearing aid or cochlear implant). In case of missing Bayley III test results, Bayley II results, other developmental test results or PARCA-R parent questionnaire results may substitute for the Bayley III test results in a hierarchical manner described in the study protocol. NDI rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.	at 24 months of age corrected for prematurity
Bayley III. Language composite score - dichotomized	The results of the language composite score of the Bayley Scales of Infant Development, 3rd edition, will be dichotomized by <85 (abnormal) versus >=85 (normal) and compared between the two treatment groups by Cochrane-Mantel-Haenszel- X²-Test.	at 24 months of age corrected for prematurity
Bayley III: Language composite score - numerical	The raw numerical data of the language-composite-score will be analysed using Wilcoxon-Mann-Whitney test. The use of this test accounts for the fact that data will be cut due to lack sensitivity below 50 points.	at 24 months corrected age
Bayley III: Cognitive composite score - dichotomized	The results of the cognitive composite score of the Bayley Scales of Infant Development, 3rd edition, will be dichotomized by <85 (abnormal) versus >=85 (normal) and compared between the two treatment groups by Cochrane-Mantel-Haenszel- X²-Test.	at 24 months of age corrected for prematurity
Bayley III: Cognitive composite score - numerical	The numerical data of the cognitive-composite-score will be analysed using Wilcoxon-Mann-Whitney test. The use of this test accounts for the fact that data will be cut due to lack sensitivity below 50 points.	at 24 months of age corrected for prematurity
Cerebral palsy	Cerebral palsy will be diagnosed if the child has a non-progressive motor impairment characterized by abnormal muscle tone and impaired range or control of movements, according to the criteria defined by the European network 'Surveillance of CP in Europe'. Rates of cerebral palsy will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.	at 24 months of age corrected for prematurity
Motor disability	Motor disability is defined as a modified GMFCS 2-5 versus a modified GMFCS 0-1, which is regarded as being normal. Rates of motor disability will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.	at 24 months of age corrected for prematurity
Score data of modified Gross Motor Function Classification Scale (GMFCS)	GMFCS-Score for quantification of the effects of cerebral palsy and other motor impairments (adapted from Palisano et al. [Palisano Med Child Neurol 1997]) using the FiO2-C-GMFCS-score sheet (separate document not part of this protocol) will be analysed. GMFCS-score consists of six categories. Analysis will be done by using Wilcoxon-Mann-Whitney test.	at 24 months of age corrected for prematurity
Bayley III: Motor composite score - numerical	The numerical data of the motor-composite-score will be analysed using Wilcoxon-Mann-Whitney test. The use of this test accounts for the fact that data will be cut due to lack of sensitivity below 50 points.	at 24 months of age corrected for prematurity
Severe visual impairment	Severe visual impairment is defined as an ophthalmological assesment indicating "severe visual impairment", e.g. the best corrected vision in the better eye yields a visual acuity less than 6/60 m (20/200 ft). Rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.	at 24 months of age corrected for prematurity
Severe hearing impairment	Severe hearing impairment is defined as need for a hearing aid or cochlear implant. Rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.	at 24 months of age corrected for prematurity

Collaborators and Investigators

• Sponsor: University Hospital Tuebingen
• Investigators: Study Director: Axel Franz, Prof. Dr., University Children's Hospital Tuebingen

Publications and helpful links

General Publications

• Maiwald CA, Niemarkt HJ, Poets CF, Urschitz MS, Konig J, Hummler H, Bassler D, Engel C, Franz AR; FiO2-C Study Group. Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants - study protocol of a randomized controlled parallel group multicenter trial for safety and efficacy. BMC Pediatr. 2019 Oct 21;19(1):363. doi: 10.1186/s12887-019-1735-9.

Helpful Links

• study homepage

Study record dates

Study Major Dates

• Study Start (Actual): July 27, 2018
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: May 18, 2017
• First Submitted That Met QC Criteria: May 23, 2017
• First Posted (Actual): May 30, 2017

Study Record Updates

• Last Update Posted (Estimated): December 27, 2023
• Last Update Submitted That Met QC Criteria: December 20, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: preterm infants; Oxygen; Oxygen saturation; closed-loop automatic control
• Additional Relevant MeSH Terms: Pregnancy Complications; Obstetric Labor Complications; Obstetric Labor, Premature; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Premature Birth
• Other Study ID Numbers: FiO2-C; 2018-000453-41 (EudraCT Number); BMBF-Fz01KG1602 (Other Grant/Funding Number: BMBF)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No